ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Biologic drugs"

  • Abstract Number: 837 • 2019 ACR/ARP Annual Meeting

    Does Discordance Between Baseline Patient’s and Evaluator’s Global Assessment of Disease Activity Impact Retention and Remission Rates of a First TNF Inhibitor in Patients with Axial Spondyloarthritis? Data from the EuroSpA Research Collaboration Network

    Brigitte Michelsen1, Lykke Midtbøll Ørnbjerg 2, Anne Gitte Loft 3, Tore Kvien 4, Adrian Ciurea 5, Herman Mann 6, Kari K. Eklund 7, Ayten Yazici 8, Maria José Santos 9, Johan Askling 10, Ziga Rotar 11, Bjorn Gudbjornsson 12, Manuel Pombo-Suarez 13, Catalin Codreanu 14, Irene van der Horst-Bruinsma 15, Eirik Kristianslund 16, Michael J. Nissen 17, Karel Pavelka 6, Nina Trokovic 18, Nevsun Inanc 19, Elsa Vieira-Sousa 20, Daniela DiGuiseppe 21, Matija Tomsic 22, Arni Jon Geirsson 23, Ruxandra IONESCU 24, Marleen van de Sande 25, Florenzo Iannone 26, Carlos Sánchez-Piedra 27, Gareth Jones 28, Lise Hyldstrup 2, Merete Lund Hetland 29 and Mikkel Østergaard 30, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, 2Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, 3Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, 4Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, 5University Hospital Zürich, Zürich, Switzerland, 6Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, 7ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, 8Kocaeli University, Faculty of Medicine, Division of Rheumatology, Kocaeli, Kocaeli, Turkey, 9Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, 10Karolinska Institutet, Stockholm, Sweden, 11UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, 12Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 13Unit Research, Spanish Society of Rheumatology, Madrid, Spain, 14Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, 15Amsterdam University Medical Center, Amsterdam, Netherlands, 16Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, 17University Hospital Geneva, Geneva, Switzerland, 18Helsinki University Central Hospital, Helsinki, Finland, 19Marmara University, Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ISTANBUL, Turkey, 20Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, 21Clinical Epidemiology Division, Dept of Medicine Solna, Karolinska Institutet,, Stockholm, Sweden, 22Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, 23Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, 24SPITALUL CLINIC SFANTA MARIA, Bucharest, 25Amsterdam UMC, Amsterdam, Netherlands, 26Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, 27Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 28University of Aberdeen, Aberdeen, United Kingdom, 29DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, 30Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark

    Background/Purpose: Discordance between baseline patient’s and evaluator’s global assessment of disease activity is common.1 However, the impact of such discordance on retention and remission rates…
  • Abstract Number: 1138 • 2019 ACR/ARP Annual Meeting

    Outpatient Costs and Evaluation and Management (E&M) Expenditure Trends in Rheumatoid Arthritis (RA) Patients Treated with Biologic Therapies in US Community Practices

    Colin Edgerton1, Janna Radtchenko 2 and V. Michael Holers 3, 1Articularis Healthcare, Charleston, 2Trio Health, La Jolla, CA, 3University of Colorado Denver, Division of Rheumatology, Aurora, CO, USA, Denver

    Background/Purpose: RA is an autoimmune disease affecting over 1.5 million Americans. Biologic disease-modifying antirheumatic drugs (bDMARDs) expanded treatment choices for RA patients (pts) in the…
  • Abstract Number: 1385 • 2019 ACR/ARP Annual Meeting

    Discontinuation of Oral Glucocorticoid After Initiation of Biological DMARDs Due to a Higher Dose of Methotrexate; A Retrospective Observational Study Based on Data from a Japanese Multicenter Registry Study

    Mochihito Suzuki1, Toshihisa Kojima 2, Nobunori Takahashi 2, Shuji Asai 2 and Naoki Ishiguro 2, 1Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan

    Background/Purpose:  In the treatment of rheumatoid arthritis (RA), glucocorticoid that provide anti-inflammatory effects is an important drug. We recommend discontinuing of glucocorticoid as soon as…
  • Abstract Number: 1499 • 2019 ACR/ARP Annual Meeting

    Golimumab Persistence in Biologic Naive and Non-Naive Patients with Axial Spondyloarthritis: Results of the GO PRACTICE Study

    René-Marc Flipo 1, Florence Tubach 2, Jean Ouaniche 3, Philippe Goupille4, Eric Lespessailles 5, Najat Gouyette 6, Naoual Harid 7, Jean-Marie Fayette 8, Philippe Bertin 9 and Bruno Fautrel 10, 1Roger Salengro University-Hospital, Lille , France, Lille, France, 2Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France, 3Private Practice , Toulon, France, Toulon, France, 4Tours University-Hospital, Tours, France, Tours, France, 5Orléans Regional Hospitals, Orléans ,France, Orléans, France, 6MSD France, Courbevoie ,France, Courbevoie, Ile-de-France, France, 7MSD France, Courbevoie, France, Courbevoie, Ile-de-France, France, 8ClinSearch, Malakoff, France, Malakoff, Ile-de-France, France, 9Limoges University-Hospital , Limoges, France, Limoges, France, 10Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France

    Background/Purpose: The pivotal GO AFTER study [1] and the ongoing observational GO BEYOND study investigate GLM efficacy in rheumatoid arthritis (RA) patients who previously received…
  • Abstract Number: 1511 • 2019 ACR/ARP Annual Meeting

    Drug Survival of Ustekinumab in Psoriatic Arthritis: A Real-World Multicentric Cohort of 252 Patients

    Jean-Guillaume Letarouilly1, Benoit Flachaire 2, Céline Labadie 3, Jérémie Sellam 4, Pascal Richette 5, Philippe Dieudé 6, Pascal Claudepierre 7, Bruno Fautrel 8, Eric Houvenagel 9, Chi Duc Nguyen 10, Marie-Hélène Guyot 11, Nicolas Segaud 12, Frédéric Maury 13, Laurent Marguerie 14, Xavier Deprez 15, Jean-Hugues Salmon 16, Guy Baudens 17, Elisabeth Gervais 18, Isabelle Chary-Valckenaere 19, Pierre Lafforgue 20, Damien Loeuille 21, Christophe Richez 22, Thao Pham 20 and René-Marc Flipo 23, 1University of Lille, CHU Lille, department of rheumatology, 59,000 Lille, France, Lille, Nord-Pas-de-Calais, France, 2Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, Provence-Alpes-Cote d'Azur, France, 3Bordeaux University, CHU Bordeaux, department of Rheumatology, 33,000 Bordeaux, France, Bordeaux, Aquitaine, France, 4Service de Rhumatologie, AP-HP Hôpital Saint-Antoine, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, Paris, France, Paris, France, 5Department of Rheumatology, AP-HP Lariboisiere Hospital, Paris, France, 6Rheumatology, Bichat Hospital, APHP, Paris;, Paris, France, 7Rheumatology, CHU Henri Mondor Créteil, Paris, France, 8Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, 9Rheumatology, Saint Philibert Hospital, Lille Cathololic Institute, Lomme, Lomme, France, 10Rheumatology, Hospital of Béthune, Béthune, Béthune, France, 11Rheumatology, Hospital of Roubaix, Roubaix, Roubaix, France, 12Internal Medicine, Hospital of Armentières, Armentières, Armentières, France, 13Rheumatology, Private Practice, Beuvry, Beuvry, France, 14Rheumatology, Calot Institute, Berck, Berck-sur-Mer, 15Rheumatology, Hospital of Valenciennes, Valenciennes, Valenciennes, France, 16Rheumatology, Reims University Hospital, Reims, Reims, France, 17Rheumatology, Private Practice, Valenciennes, Valenciennes, France, 18CHU de Poitiers, Rheumatology, Poitiers, France, 19Centre Hospitalier Universitaire de Nancy, VANDOEUVRE, France, 20Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, 21Rheumatology, Nancy University Hospital and and UMR 7365 CNRS-UL IMoPA, Université de Lorraine, VANDOEUVRE, France, 22Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France, 23University of Lille, CHU Lille, department of rheumatology, 59,000 Lille, France, Lille, France

    Background/Purpose: Ustekinumab (UST) is a new biological Disease-modifying AntiRheumatic Drug (bDMARD) available in psoriatic arthritis (PsA), targeting respectively IL12-23. Real-world data are missing for this…
  • Abstract Number: 1529 • 2019 ACR/ARP Annual Meeting

    The Efficacy and Safety of Anti-TNFα Treatment in Ankylosing Spondylitis Patients with Late Onset Compared to Those with Adult Onset; The Data from TURKBIO Registry

    Sadettin Uslu1, Gercek Can 2, Ayşe Cefle 3, Sema Yılmaz 4, Sinem Burcu Kocaer 5, Tuba Yüce İnel 1, Semih Gülle 1, Süleyman Serdar Koca 6, Servet Yolbaş 7, Mehmet Akif Öztürk 8, Soner Senel 9, Nevsun Inanc 10, Ediz Dalkılıç 11, Ozgül Gunduz 12, Abdurrahman Tufan 8, Servet Akar 13, Merih Birlik 5, Ismail Sari 1, Nurullah Akkoç 12 and Fatos Onen 14, 1Division of Rheumatology, Dokuz Eylül University School of Medicine, İzmir, Turkey, Izmir, Turkey, 2Dokuz Eylul University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Izmir, Turkey, 3Division of Rheumatology, Kocaeli University School of Medicine, Kocaeli, Turkey, Kocaeli, Turkey, 4Division of Rheumatology, Selcuk University School of Medicine, Konya, Turkey, Konya, Turkey, 5Division of Rheumatology, Dokuz Eylül University School of Medicine, İzmir, Turkey, Turkey,Izmir, Izmir, Turkey, 6Fırat University School of Medicine Division of Rheumatology, Elazığ, Turkey, 7Division of Rheumatology, Inonu University School of Medicine, Malatya, Turkey, Malatya, Turkey, 8Division of Rheumatology, Gazi University School of Medicine, Ankara, Turkey, Ankara, Turkey, 9Division of Rheumatology, Erciyes University School of Medicine, Kayseri, Turkey, Kayseri, Turkey, 10Marmara University, Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ISTANBUL, Turkey, 11Uludağ University, Bursa, Turkey, 12Division of Rheumatology, Celal Bayar University School of Medicine, Manisa, Turkey, Manisa, Turkey, 13Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, 14Dokuz Eylul University School of Medicine, Division of Rheumatology, İzmir, Turkey

    Background/Purpose: The first symptoms of ankylosing spondylitis (AS) patients usually begin prior to 45 years, but can occur later in life. The purpose of this…
  • Abstract Number: 1901 • 2019 ACR/ARP Annual Meeting

    Serious Infections in Offspring Exposed in Utero to Non-TNFi Biologics and Tofacitinib

    Evelyne Vinet1, Yvan St-Pierre 1, Cristiano S. Moura 1, Jeffrey Curtis 2 and Sasha Bernatsky 3, 1McGill University Health Centre, Montreal, QC, Canada, 2University of Alabama at Birmingham, Birmingham, AL, 3Research Institute of the McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: During pregnancy, maternal circulating immunoglobulins G (IgG) are actively transported across the placenta through their Fc portion. Thus, TNFi and other biologics harbouring an Fc…
  • Abstract Number: 2111 • 2019 ACR/ARP Annual Meeting

    Symptomatic Coccidioidomycosis Infections in Patients on Biologic Therapies

    Alexander Peck1, Ella Starobinska 2, Gilbert Ortega 1, Travis Maestas 1, Jaclyn Leong 1, Phan Saligrama 1, Jawad Bilal 1 and Dominick Sudano 3, 1University of Arizona College of Medicine, Tucson, AZ, 2University of Arizona College of Medicine, Tucson, AL, 3Banner University Medical Center Tucson, Tucson

    Background/Purpose: Studies have shown an increased risk of coccidioidomycosis infection in immunosuppressed patients. However, relationship of coccidioidomycosis infections with different immunosuppressive medication is not well…
  • Abstract Number: 2398 • 2019 ACR/ARP Annual Meeting

    Prevalence of Anxiety and Depression in a Cohort of Patients with Rheumatic Diseases on Biological Infusions

    Alexander Peck1, Ella Starobinska 2, Gilbert Ortega 1, Jaclyn Leong 1, Travis Maestas 1, Phan Saligrama 1, Jawad Bilal 1 and Dominick Sudano 3, 1University of Arizona College of Medicine, Tucson, AZ, 2University of Arizona College of Medicine, Tucson, AL, 3Banner University Medical Center Tucson, Tucson

    Background/Purpose: Studies have shown an increased prevalence of psychologic disorders in rheumatic diseases, such as rheumatoid arthritis, systemic lupus erythematosus, and psoriatic arthritis, compared to…
  • Abstract Number: 2406 • 2019 ACR/ARP Annual Meeting

    Hepatobiliary Events in >5000 Patients with Inflammatory Arthritis Treated with Biosimilar or Originator Etanercept in Routine Care, Results from the Danish Nationwide DANBIO Registry

    Bente Glintborg 1, Stylianos Georgiadis 2, Mette Nørgaard 3, Frank Mehnert 3, Kathrine Lederballe Grøn 1, Niels Steen Krogh 4 and Merete Lund Hetland1, 1DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, 2DANBIO registry and Copenhagen Center for Arthritis Research, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, 3Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark, 4Zitelab / DANBIO, Copenhagen, Denmark

    Background/Purpose: Marketing of biosimilar biological drugs may significantly reduce drug costs if comparable safety and efficacy of originator and the biosimilar can be documented. In…
  • Abstract Number: 205 • 2019 ACR/ARP Annual Meeting

    Does a Mandatory Non-medical Switch from Originator to Biosimilar Etanercept Lead to Increase in Healthcare Use and Costs? A Danish Register-based Study of 1620 Patients with Inflammatory Arthritis

    Bente Glintborg 1, Rikke Ibsen 2, Rebekka Elisabeth Qwist Bilbo 3, Merete Lund Hetland1 and Jakob Kjellberg 3, 1DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, 2i2minds, Aarhus, Denmark, 3VIVE, The Danish Centre for Social Science Research, Copenhagen, Denmark

    Background/Purpose: Marketing of cheaper biosimilar biological agents has created financial incentives for switching from the corresponding originator drugs (=non-medical switch). The economic benefit might potentially…
  • Abstract Number: 2464 • 2019 ACR/ARP Annual Meeting

    Multidisciplinary Unit of Psoriatic Arthritis: Clinical Results

    Clara Pérez-Velásquez1, Oihane Ibarguengoitia-Barrena 2, David Montero-Seisdedos 2, Lucía Vega-Alvarez 2, Carmen García-Gómez 1, Eva Galindez-Agirregoikoa 3, Silvia Pérez-Barrio 4, María Esther Ruiz-Lucea 2, Ignacio Torre-Salaberri 2, Ana Rosa Intxaurbe-Pellejero 2, Olaia Fernandez-Berrizbeitia 1, Juan María Blanco-Madrigal 2, Eduardo Cuende-Quintana 2, Itziar Calvo-Zorrilla 2, Iñigo Gorostiza-Hormaeche 5, Natalia Andrea Rivera-García 2, María Jesus Allande-López-Linares 2, Helena Ugarte-Zuazo 2 and María García-Vivar 1, 1University Hospital of Basurto, Bilbao, Pais Vasco, Spain, 2Rheumatology Unit, Basurto University Hospital, Bilbao, Spain, Bilbao, Spain, 3Hospital de Basurto, Bilbao, Pais Vasco, Spain, 4University Hospital of Basurto, Dermatology Department, Bilbao, Pais Vasco, Spain, 5Investigation Unit, Basurto University Hospital, Bilbao, Spain, Bilbao, Spain

    Background/Purpose: The multidisciplinary unit of psoriatic arthritis (PsA) are attractive to improve the early diagnosis and optimize the management of complex patients with PsA. There…
  • Abstract Number: 248 • 2019 ACR/ARP Annual Meeting

    Adherence to Biologic Disease-modifying Anti-rheumatic Drugs (DMARDs) —a Comparison of Long-term Adherence Among Patients with Various Inflammatory Conditions by Primary Dispensing Channel

    Caroline Swift 1, Yvonne Viteri2, Gail Bridges 3, Mary Dorholt 4 and Monal Kohli 5, 1Express Scripts, St. Louis, MO, 2Accredo, Northvale, NJ, 3Accredo, Memphis, TN, 4Accredo, Maple Grove, MN, 5Express Scripts, Franklin Lakes, NJ

    Background/Purpose: Medication adherence to biologic DMARDs has been associated with optimal clinical outcomes. Adherence varies with primary dispensing channel among rheumatoid arthritis patients. Prior studies…
  • Abstract Number: 2731 • 2019 ACR/ARP Annual Meeting

    Decomposition Analysis of Spending and Price Trends for Biologic Anti-Rheumatic Drugs in Medicare and Medicaid

    Natalie McCormick1, Zachary Wallace 2, Chana Sacks 3, John Hsu 4 and Hyon K. Choi 5, 1Massachusetts General Hospital and Harvard Medical School, Boston, MA, 2Massachusetts General Hospital, Boston, 3Department of General Internal Medicine, Massachusetts General Hospital; Department of Medicine, Harvard Medical School, Boston, MA, 4Mongan Institute, Massachusetts General Hospital; Department of Health Care Policy, Harvard Medical School, Boston, MA, 5Massachusetts General Hospital, Boston, MA

    Background/Purpose: Billions of public dollars are spent each year on biologic disease-modifying anti-rheumatic drugs (bDMARDs), but the drivers of bDMARD spending and per-patient cost increases…
  • Abstract Number: 276 • 2019 ACR/ARP Annual Meeting

    Effectiveness of Screening by Nurse with Predetermined Questionnaire on Infections Before Administration of Intravenous Biologics in Patients with Rheumatoid Arthritis

    Sayaka Furukawa1, Sho Fukui 1, Sakura Tamaki 2, Tomoko Nakasone 3 and Masato Okada 4, 1St.Luke's International Hospital, Chuo-ku, Tokyo, Japan, 2St. Luke's International Hospital, Chuo-ku, Japan, 3St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, 4St. Luke's International Hospital, Tokyo, Japan

    Background/Purpose: Biologics are widely used as treatment for rheumatoid arthritis (RA), and pre-administration screening of active infection is imperative for the safety use. There is…
  • 1
  • 2
  • 3
  • …
  • 14
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology